U.S. markets close in 44 minutes

Halozyme Therapeutics, Inc. (HALO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
43.60+1.83 (+4.37%)
As of 3:15PM EDT. Market open.
Sign in to post a message.
  • A
    AJ111
    I am baffled beyond I can express as what it is that is keeping HALO from going up and be in the 50's as oppose to very low $40's even on a day such as today when growth stocks are all up significantly (except HALO lagging). What is the mystery behind this lagging....?
  • M
    Mathew Fuji
    Most revenue strong biotechs are enduring this same fate these days. Look at RGEN. Same thing there too. These are dynamic high potential growth biotechs that remain independent of PDUFAs since they are linked to huge numbers of deals. Rebound will be strong and $50 (short term) has already been written
    Bullish
  • S
    Sean 007
    Forward PE ratio = 16
    PEG ratio 1.08

    Halozyme is a great value stock with with top and bottomline growth, high profit margin and a moat around its platform.
  • S
    Sean 007
    fortunately for us, Halozyme is not a hype stock. Most of the growth stock that are suffering now are the ones hyped by either the REDDIT crowd or certain analyst/managers talking their own book. Halozyme is not even on the radar screen of vast majority of retail investors. Just look at the % of institutional holdings vs. retail. You don’t hear about Halozyme on CNBC, bloomberg or on youtube. This is why I love it. This is also why it is trading at such low forward PE multiple compared to it’s peers in biotech sector (look at my earlier posts/references). It’s under-appreciated and there is zero hype about it.
  • S
    Sean 007
    Here is why it’s a steal to buy at these prices (from Nasdaq dot kom), Halozyme’s PE ratios:

    2021 Estimates
    28.13
    2022 Estimates
    16.4
    2023 Estimates
    13.53
  • A
    AJ111
    Not that this really matters but yet curious to know... does anyone have the text reason for Piper Sandler analyst's downgraded of HALO from Overweight to Neutral and lowering target from $50 - $48....? What did he hear in the CC call yesterday or in the report for him to downgrade the stock...?
  • J
    Joseph
    For what it’s worth, I just realized that HALO’s closing price these past 2 days was lower than the average price HALO paid in its Q1 repurchase program.

    Recall that $125 M was the planned repurchase for all of 2021. In Q1, HALO spent $76 M, or 60.8%, of the targeted 2021 total dollar amount for repurchases.

    Based on average prices HALO reportedly paid in its repurchase program through March 31, 2021, and December 31, 2020, respectively, reasonable inferences can be made that, in Q1, HALO repurchased roughly 1,766,800 shares, at an average price of approximately $43.02.

    I’m interested to see how effectively the repurchase program will be in the remainder of 2021. On the one hand, HALO has been smart in the past with its repurchase dollars. On the other, I wonder whether the 39.8% left in 2021’s target can make much of a dent, especially if the market corrects.
  • P
    Patrick
    A bit anxious about tomorrows q1 earnings call because HALO has missed analysts eps expectations 3 out of the last 4 qtrs. Really like this companies story long-term and see a lot of growth with all of the drugs in various phases of testing using Enhanze, but they need to hit the numbers. The way I view HALO, if they can hit the numbers for 2021 ($389m revenue, $1.55 eps) and for 2022 ($585m revenue, $2.66eps), growing revenue by 45-50% annually and growing eps by 60-65%, and using a conservative pe of 45, I would expect share price to be around $70 by end of year and around $120 by end of 2022. I could live with that. Just my opinion.
    Bullish
  • A
    AJ111
    Fair value for the HALO stock is $74. Here is why:

    Current market cap as of close of market 5/10 = $6.6billion

    They Reiterate 2021 GAAP Operating Income Guidance of $215 million to $235 million, Representing 49%-63% Growth over 2020 GAAP Operating Income -

    P/e = 30 taking into account the lower range of earnings

    PEG = 30 / 49% growth (taking lower range) = 0.61

    Obviously way undervalued. For PEG to be at 1 for stock to be at faire value market cap needs to raise to about $10.5 billion or a stock price of about $74 (and this is conservatively taking the lower range of $215 million earnings with only about 49% growth rate).
  • J
    Jim
    It appears that what one needs to do at this point with HALO is sell it just before earnings and then buy it back a week afterwards. Then rinse and repeat.
  • M
    Mathew Fuji
    I think there is an extremely strong progress. It will take me sometime to digest the entire cal. Need to listen in again. Many moving parts to the story. One of the strongest and stable growths in small biotechs. Too many positive pieces I heard today’s call!!
    Bullish
  • S
    Sean 007
    When a great company is offered at a 30% discount (from all time high of $56) despite fantastic fundamentals, smart investors take advantage. History repeats itself. Have a look at how quickly it went up last time we had a 30% hair cut.
  • J
    Jim
    It's hard to gage the true reaction of the quarters earnings and cc on a market day like today. I suspect it'll take a few days if not a couple weeks to get the true reaction via institutional investors.
  • J
    Jim
    Keep in mind that Helen is presenting tomorrow at the BofA Securities 2021 Health Care Conference. IMO That's a big plus after these solid earnings.
  • J
    Jim
    Halozyme Reports First Quarter 2021 Results

    Share This
    05/10/2021
    - First Quarter Revenue of $89.0 million, Up from $25.4 million in First Quarter of 2020 -
    - Record Quarterly Royalties in the First Quarter of $36.9 million Representing 119% Growth over First Quarter 2020 -
    - Reiterate 2021 Revenue Guidance of $375 Million to $395 Million Representing 40% to 48% Growth over 2020 Revenue -
    - Reiterate 2021 GAAP Operating Income Guidance of $215 million to $235 million, Representing 49%-63% Growth over 2020 GAAP Operating Income -
  • S
    Sean 007
    I hope everyone noticed that there is a new HIV trial. Take a look at slide 5 of today’s presentation. The old/existing HIV trial was for a vaccine. The new one is for a treatment. It’s an antibody treatment. The infectious disease indication is coming along nicely albeit slowly. I still believe we will have Enhanze enabled mab’s for flu and covid so that future viral mutations that scape the vaccines can be treated early with mab’s before patients get so sick that they need hospitalization. This will be a huge market for halozyme. Multimodal approach to pandemics is best practice.
  • M
    Mathew Fuji
    $50 is written in stone so if I add today a 20% short term gain over few weeks or months is high potential. Thoughts?
  • J
    Jim
    Piper Sandler analyst downgraded from Overweight to Neutral. Lowered target from $50 - $48.
  • M
    Mathew Fuji
    Those who have been here know that historically particularly during the pancreatic trial days HALO used to rise steadily the day before ER and drop after release. Then would pull right back up. On numerous occasions I pulled in stock as low as $8s. Was almost ready to sell on the rise to $19+ before the transformation happens and clarity on sustainable profits emerged. Well then it has steadily added to the gains. We shall also hear today how much buyback for the year remains.
    Very happy here with my hold and sitting on ammo to pull in more if at all a dip happens!!!
    Have many colleagues who are all biotech seniors and strongly vested here for long!!!
  • M
    Mathew Fuji
    IMHO it is a beat whichever way you look at it haha 😂 Now whatever the market decides to do with it is either an opportunity to add or just hold strong as far as a retail like me is concerned!! Will listen into the call for more clarity!!
    Bullish